

I. Epidemiological profile

Population	2015	%
High transmission (> 1 case per 1000 population)	230 000	86
Low transmission (0-1 cases per 1000 population)	39 000	14
Malaria-free (0 cases)	0	0
Total	269 000	

<b>Parasites and vectors</b>	
Major plasmodium species: <i>P. falciparum</i> (47%), <i>P. vivax</i> (53%)	
Major anopheles species: <i>An. darlingi</i>	
Reported confirmed cases:	434 Estimated cases: 730 [470-1500]
Reported deaths:	0 Estimated deaths: <10


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2012
	ITNs/LLINs distributed to all age groups	Yes	2012
<b>IRS</b>	IRS is recommended	Yes	-
	DDT is authorized for IRS	No	-
<b>Larval control</b>	Use of larval control recommended	Yes	-
<b>IPT</b>	IPT used to prevent malaria during pregnancy	N/A	-
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	No	-
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	-
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	Yes	-
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring of adverse reactions to antimalarials exists	Yes	-
<b>Surveillance</b>	ACD for case investigation (reactive)	No	-
	ACD of febrile cases at community level (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-

<b>Antimalaria treatment policy</b>		Medicine	Adopted				
First-line treatment of unconfirmed malaria		-	-				
First-line treatment of <i>P. falciparum</i>		AL	-				
Treatment failure of <i>P. falciparum</i>		AQ+PG	-				
Treatment of severe malaria		AS; AL	-				
Treatment of <i>P. vivax</i>		CQ+PQ	-				
Dosage of primaquine for radical treatment of <i>P. vivax</i>		-	-				
Type of RDT used		Pf + all species (Combo)					
<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
-	-	-	-	-	-	-	-
<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>							
Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
2010-2014	-	-	-	-	-		

III. Financing

Sources of financing




Government expenditure by intervention in 2015


No data reported for 2015

IV. Coverage


ITN and IRS coverage




Cases tested and treated in public sector



Cases tracked




Test positivity



V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

